Physician profile
Gillian Esser
NPI 1598768491
$2,424.36
in general payments reported to CMS, 2019-2025
24 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $248 · 2021: $344 · 2022: $567 · 2023: $188 · 2024: $354 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $943.91 | 2022-2025 | |
| Abbvie INC. | $292.92 | 2020-2025 | |
| Therapeuticsmd, INC. | $251.65 | 2019-2022 | |
| Avion Pharmaceuticals | $174.70 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $101.03 | 2020-2023 | |
| Scynexis, INC. | $61.20 | 2022 | |
| Shield Therapeutics INC | $57.03 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $56.25 | 2019 | |
| Ironwood Pharmaceuticals, INC | $51.28 | 2020 | |
| Evofem Biosciences, INC. | $49.91 | 2021-2022 | |
| Allergan, INC. | $49.24 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.35 | 2022 | |
| Ibsa Pharma INC. | $39.58 | 2022-2023 | Tirosint, Licart |
| Baxter Healthcare | $36.19 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.61 | 2020-2024 | Xifaxan, Trulance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $31.44 | 2021 | |
| Lilly USA, LLC | $25.74 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $20.24 | 2020 | |
| Agile Therapeutics, INC. | $20.14 | 2022 | |
| Radius Health, INC. | $19.95 | 2020 | |
| Lupin INC. | $18.66 | 2020 | |
| Daiichi Sankyo INC. | $17.28 | 2021 | |
| Novo Nordisk INC | $15.88 | 2024 | Rybelsus, Ozempic |
| Hologic Sales and Service, LLC | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Esser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.